- Home
- CSAN vs IRON Comparison
CSAN vs IRON Comparison
Compare CSAN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSAN
- IRON
- Stock Information
- Founded
- CSAN 1936
- IRON 2017
- Country
- CSAN Brazil
- IRON United States
- Employees
- CSAN 12090
- IRON N/A
- Industry
- CSAN Retail-Auto Dealers and Gas Stations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- CSAN Consumer Discretionary
- IRON Health Care
- Exchange
- CSAN Nasdaq
- IRON Nasdaq
- Market Cap
- CSAN 2.1B
- IRON 2.1B
- IPO Year
- CSAN N/A
- IRON N/A
- Fundamental
- Price
- CSAN $4.35
- IRON $68.02
- Analyst Decision
- CSAN Hold
- IRON Strong Buy
- Analyst Count
- CSAN 3
- IRON 10
- Target Price
- CSAN $9.47
- IRON $97.80
- AVG Volume (30 Days)
- CSAN 2.4M
- IRON 340.9K
- Earning Date
- CSAN 11-12-2025
- IRON 11-11-2025
- Dividend Yield
- CSAN N/A
- IRON N/A
- EPS Growth
- CSAN N/A
- IRON N/A
- EPS
- CSAN N/A
- IRON N/A
- Revenue
- CSAN $7,993,490,490.00
- IRON N/A
- Revenue This Year
- CSAN $270.07
- IRON N/A
- Revenue Next Year
- CSAN $1.31
- IRON N/A
- P/E Ratio
- CSAN N/A
- IRON N/A
- Revenue Growth
- CSAN 7.98
- IRON N/A
- 52 Week Low
- CSAN $3.80
- IRON $30.82
- 52 Week High
- CSAN $9.76
- IRON $69.87
- Technical
- Relative Strength Index (RSI)
- CSAN 38.97
- IRON 66.16
- Support Level
- CSAN $4.39
- IRON $65.26
- Resistance Level
- CSAN $4.56
- IRON $69.87
- Average True Range (ATR)
- CSAN 0.20
- IRON 2.52
- MACD
- CSAN -0.11
- IRON 0.54
- Stochastic Oscillator
- CSAN 2.05
- IRON 80.55
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.